ESMO 2017 | Is carboplatin an effective addition in the treatment of breast cancer?

Sibylle Loibl, MD, PhD, from the University of Frankfurt, Frankfurt, Germany, talks to us about her presentation concerning the GeparSixto study (NCT01426880). This was a Phase III clinical trial examining the efficacy of adding carboplatin to standard chemotherapy in the treatment of triple-negative and HER2-positive early breast cancer. Prof. Liobl discusses the results of the study and how this data corresponded with follow-up work assessing disease-free survival in these patients. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.